Introduction

As part of the Egyptian Drug Authority’s (EDA) commitment to the highest standards of transparency and governance, the composition of the EDA Board of Directors includes a number of ministers, representing the State as a public legal entity, to ensure the highest level of governmental coordination and to facilitate the fulfillment of the Authority’s mandate. A clear separation is maintained between policy-making and operational functions. The Board of Directors is responsible for establishing the Authority’s general policies and strategic directions, while all executive, technical, and regulatory activities—including licensing, inspection, and regulatory oversight—are carried out independently by the competent sectors without any intervention from the Board.

Furthermore, the composition of the Board does not include any representatives of pharmaceutical companies, manufacturers, chambers of commerce, or pharmaceutical industry chambers (as representatives of stakeholders under the relevant laws and regulations), thereby ensuring the independence and complete impartiality of the Board’s decisions.

The Authority reaffirms its continued commitment to implementing the highest international standards of transparency to ensure the safety, quality, and efficacy of medicines, as well as the effectiveness of its regulatory oversight. *

Formation of the Board of Directors of the Egyptian Drug Authority

His Excellency President Abdel Fattah El-Sisi issued Republican Decree No. 28 of 2026 on January 12, 2026, regarding the reconstitution of the Board of Directors of the Egyptian Drug Authority. The Board shall be chaired by Dr. Ali Mohammad Abd Al-Salam Al-Ghamrawy (with the rank of Minister), with Dr. Tamer Mohammad Ahmad Elhusseiny as Vice Chairman (with the rank of Deputy Minister), and the membership of:

• Minister of Health and Population.
• Minister of Industry.
• Minister of Investment and Foreign Trade.
• Chairman of the Board of Directors of the Egyptian Authority for Unified Procurement.
• Chairman of the General Authority for Healthcare Accreditation and Regulation.
• A Head of a Sector within the Authority, selected by the Chairman of the Board.
• An academic member from the Faculties of Pharmacy with experience in the Authority's field of work, selected by the Prime Minister.
• Two members with experience in the Authority's field of work, selected by the Prime Minister based on the nomination of the Chairman of the Authority's Board of Directors.
• A representative of the Union of Medical Professions Syndicates.
• A representative of civil society organizations with experience in the Authority's field of work, selected by the Prime Minister.

The Board of Directors may invite any experts or specialists deemed necessary to attend board meetings, without having a counted vote in the deliberations.

The term of membership in the Board of Directors shall be one year, effective from January 12, 2026.

* References:

• Constitution of the Arab Republic of Egypt.
• Law No. 189 of 1951 concerning Chambers of Commerce.
• Law No. 70 of 2019 promulgating the Law on the Federation of Egyptian Industries and Industrial Chambers.
• Law No. 151 of 2019 promulgating the Law Establishing the Egyptian Drug Authority.